Ubs Group Ag Puma Biotechnology, Inc. Transaction History

Ubs Group Ag

$527 Billion
Q4 2024

A detailed history of Ubs Group Ag transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 155,571 shares of PBYI stock, worth $547,609. This represents 0.0% of its overall portfolio holdings.

Number of Shares

155,571

Previous 27,094 474.19%

Holding current value

$547,609

Previous $69,000 586.96%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.42 - $3.39 $310,914 - $435,537	128,477 Added 474.19%	155,571 $474,000
Q3 2024 Nov 14, 2024	BUY	$2.25 - $4.03 $15,225 - $27,271	6,767 Added 33.29%	27,094 $69,000
Q2 2024 Aug 13, 2024	BUY	$2.92 - $5.83 $28,277 - $56,457	9,684 Added 90.99%	20,327 $66,000
Q1 2024 May 13, 2024	SELL	$4.29 - $7.4 $2,059 - $3,552	-480 Reduced 4.32%	10,643 $56,000
Q4 2023 Feb 09, 2024	BUY	$2.23 - $4.49 $17,208 - $34,649	7,717 Added 226.57%	11,123 $48,000
Q3 2023 Nov 09, 2023	SELL	$2.63 - $4.09 $1,720 - $2,674	-654 Reduced 16.11%	3,406 $8,000
Q2 2023 Aug 11, 2023	SELL	$2.6 - $3.58 $17,849 - $24,576	-6,865 Reduced 62.84%	4,060 $14,000
Q1 2023 May 12, 2023	BUY	$2.21 - $4.82 $16,541 - $36,077	7,485 Added 217.59%	10,925 $33,000
Q4 2022 Feb 08, 2023	BUY	$2.12 - $5.08 $31 - $76	15 Added 0.44%	3,440 $14,000
Q3 2022 Nov 10, 2022	SELL	$2.27 - $3.84 $2,528 - $4,277	-1,114 Reduced 24.54%	3,425 $8,000
Q2 2022 Aug 10, 2022	SELL	$1.64 - $3.3 $35,171 - $70,771	-21,446 Reduced 82.53%	4,539 $13,000
Q1 2022 May 16, 2022	BUY	$2.13 - $3.24 $18,153 - $27,614	8,523 Added 48.81%	25,985 $75,000
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $31,173 - $71,972	10,938 Added 167.66%	17,462 $53,000
Q3 2021 Nov 15, 2021	SELL	$6.63 - $9.39 $24,935 - $35,315	-3,761 Reduced 36.57%	6,524 $46,000
Q2 2021 Aug 13, 2021	SELL	$8.98 - $11.6 $422,517 - $545,791	-47,051 Reduced 82.06%	10,285 $94,000
Q1 2021 May 12, 2021	BUY	$9.38 - $13.63 $450,690 - $654,894	48,048 Added 517.31%	57,336 $557,000
Q4 2020 Feb 11, 2021	SELL	$7.78 - $12.13 $1.16 Million - $1.82 Million	-149,670 Reduced 94.16%	9,288 $95,000
Q3 2020 Nov 12, 2020	SELL	$9.5 - $11.14 $5,044 - $5,915	-531 Reduced 0.33%	158,958 $1.6 Million
Q2 2020 Jul 31, 2020	SELL	$7.01 - $13.24 $35,106 - $66,305	-5,008 Reduced 3.04%	159,489 $1.66 Million
Q1 2020 May 01, 2020	BUY	$6.28 - $14.57 $931,474 - $2.16 Million	148,324 Added 917.11%	164,497 $1.39 Million
Q4 2019 Feb 14, 2020	SELL	$6.5 - $10.73 $1.45 Million - $2.39 Million	-222,615 Reduced 93.23%	16,173 $142,000
Q3 2019 Nov 14, 2019	BUY	$8.75 - $12.85 $1.97 Million - $2.89 Million	224,627 Added 1586.24%	238,788 $2.57 Million
Q2 2019 Aug 14, 2019	SELL	$12.3 - $35.76 $137,243 - $399,010	-11,158 Reduced 44.07%	14,161 $180,000
Q1 2019 May 14, 2019	SELL	$20.77 - $42.37 $3.47 Million - $7.08 Million	-166,990 Reduced 86.83%	25,319 $982,000
Q4 2018 Feb 14, 2019	BUY	$20.07 - $46.7 $2.66 Million - $6.2 Million	132,663 Added 222.42%	192,309 $3.91 Million
Q3 2018 Nov 14, 2018	BUY	$41.2 - $59.85 $777,773 - $1.13 Million	18,878 Added 46.31%	59,646 $2.74 Million
Q2 2018 Aug 14, 2018	SELL	$48.3 - $68.25 $1.48 Million - $2.09 Million	-30,683 Reduced 42.94%	40,768 $2.41 Million
Q1 2018 May 15, 2018	SELL	$59.7 - $99.25 $7.23 Million - $12 Million	-121,029 Reduced 62.88%	71,451 $4.86 Million
Q4 2017 Feb 14, 2018	BUY	$93.85 - $132.45 $13.7 Million - $19.4 Million	146,362 Added 317.36%	192,480 $19 Million
Q3 2017 Nov 14, 2017	SELL	$72.0 - $119.75 $1.01 Million - $1.68 Million	-14,008 Reduced 23.3%	46,118 $5.52 Million
Q2 2017 Aug 14, 2017	SELL	N/A	-13,658 Reduced 18.51%	60,126 $5.26 Million
Q1 2017 Nov 14, 2017	BUY	N/A	73,784	73,784 $2.75 Million

Others Institutions Holding PBYI

# of Institutions

110

Shares Held

28.3M

Call Options Held

27.9K

Put Options Held

3.4K

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $160M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account